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Parkinsondisease (PD) is a commonneurodegenerative disorder,
which involves the deterioration of dopaminergic neurons in the
pars compacta of the substantia nigra. The etiology of PD is still
unknown, but recent identification of mutations in familial cases of
PD has advanced the understanding of the molecular mechanisms
of this neurological disease. Mutations in the parkin gene, which
encodes for ubiquitin-protein ligase (E3), have been implicated in
autosomal recessive juvenile Parkinsonism, an early onset and com-
mon familial form of PD. Here we reported that Parkin selectively
binds to RanBP2, which is localized in the cytoplasmic filament of
thenuclear pore complex andbelongs to the small ubiquitin-related
modifier E3 ligase family. We also demonstrated that RanBP2
becomes a target for Parkin E3 ubiquitin-ligase and is processed via
Parkin-mediated ubiquitination and subsequent proteasomal deg-
radation. Furthermore, Parkin controls the intracellular levels of
sumoylated HDAC4, as a result of the ubiquitination and degrada-
tion of RanBP2. Our findings suggested that the intracellular levels
of RanBP2 and its functional activity may be modulated by Parkin-
mediated ubiquitination and proteasomal pathways.
Parkinson disease (PD)2 is a major neurodegenerative disease char-
acterized by a distinct set of movement disorders, including muscle
rigidity, tremor, and bradykinesia (1). In PD, the level of dopamine is
decreased in the striatum, most severely in the putamen. This is largely
a result of the deterioration of dopaminergic neurons in the substantia
nigra pars compacta (2–4). The etiology of PD remains poorly under-
stood, but several genetic loci have been implicated in the pathogenesis
of familial forms of PD. First, two missense mutations of -synuclein
have been linked to a rare dominant form of PD (5). Second, parkin has
been identified as the causative gene of early onset autosomal recessive
juvenile parkinsonism (AR-JP) (6), and amissensemutation in the ubiq-
uitin (Ub) C-terminal hydrolase L1 appears to be responsible for a dom-
inant form of PD (7). Most recently, mutations in DJ-1 and PTEN-
induced putative kinase-1 have been correlated with the incidences of
familial PD (8, 9).
The structure of Parkin contains a C-terminal RING-IBR-RING
motif and an N-terminal region with homology to ubiquitin (10–12).
Proteins destined to degrade in the proteasomes are subject to covalent
modification by ubiquitin as a small protein tag. Ubiquitination pro-
ceeds through a sequential enzymatic reaction composed of ubiquitin-
activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiq-
uitin-protein ligase (E3) (13). Based on the previous findings that
numerous proteins with RING finger motifs have E3 ubiquitin-ligase
activity, several studies have revealed that Parkin has an ubiquitin E3
ligase activity. The exquisite specificity for the proteins to be ubiquiti-
nated is usually determined by a diverse family of E3s with a specific E2.
Based on the functional role of Parkin, it can be surmised that the loss
of Parkin results in the gradual and abnormal accumulation of Parkin
substrates, which might then induce a familial PD syndrome. Several
substrates of Parkin have been reported to date, including cell division
control-related protein-1 (CDCrel-1; Ref. 13), synphilin-1 (14), Pael-R
(10, 15), -synuclein (16, 17), the p38 subunit of aminoacyl-tRNA syn-
thetase (18), cyclin E (19), /-tubulin (20), and polyglutamine protein
(21).
Here we attempted to identify the new binding targets of Parkin by
using yeast two-hybrid assay. As the result of screening human fetal
cDNA library, RanBP2was identified to bind selectively to Parkin. Using
co-immunoprecipitation, in vitro GST pull-down assay, and immuno-
cytochemical analysis, we detected the occurrence of specific interac-
tions between Parkin and RanBP2 in mammalian neuronal systems as
well as in non-neuronal cells. In addition, RanBP2was shown to become
a substrate of Parkin E3 ubiquitin ligase and to be subsequently pro-
cessed via the proteasomal machinery.
EXPERIMENTAL PROCEDURES
Materials and cDNA Constructs—Synthetic dropout medium and
yeast extract peptone dextrose containing adenine were purchased
from Qbiogene (Carlsbad, CA). 3-Amino-1,2,4-triazole was from
Sigma, and the human fetal brain cDNA library was from Clontech.
Peroxidase-conjugated anti-rabbit and anti-mouse immunoglobulins
were from Zymed Laboratories Inc.. Dulbecco’s modified Eagle’s
medium, fetal bovine serum, and cell culture reagents were from
Invitrogen. Protein A-Sepharose was from Amersham Biosciences, and
enhanced chemiluminescence (ECL) reagents were obtained from
PerkinElmer Life Sciences. Polyclonal and monoclonal anti-HA, anti-
GFP, anti-GST, and anti-RanBP2 antibodies were from Santa Cruz Bio-
technology (Santa Cruz, CA); anti-FLAG antibody was from Sigma, and
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polyclonal anti-Parkin antibodies were from cell signaling and Chemi-
con. Clasto-lactacystin -lactone was purchased from A. G. Scientific
(San Diego), and calpeptin was from Calbiochem. Mammalian expres-
sion vector encoding for FLAG-tagged Parkinwas kindly provided byG.
Lee (Ajou University, Suwon, Korea). Plasmids encoding for bacterial
recombinant GST fused with wild type and deleted Parkin mutants
(77–465 and 1–170) and mammalian expression vectors encoding
GFP-tagged wild type Parkin were gifts from H. Rhim (The Catholic
University, Seoul, Korea). Plasmids encoding for recombinant GST-
tagged deletion mutants of human RanBP2, such as containing the
amino acids 2596–2836 (GST-IR) and 2633–2761 (GST-IR1 2), and
pEGFP-Cl vector for GFP-tagged IR1  2 were provided by H. Saitoh
(Kyushu University, Fukuoka, Japan). Mammalian expression vectors
for HA-tagged SUMO-1 and GFP- and FLAG-tagged HDAC4 were
provided by A. Dejean (Institut Pasteur, Paris, France). Plasmid encod-
ing His-tagged Nedd4-2 was provided by P. Snyder (University of Iowa,
Iowa City).
Yeast Two-hybrid Assay—The bait vector for yeast two-hybrid assay
was constructed by subcloning the wild type Parkin cDNA into the
pHybTrp/Zeo vector. The human fetal cDNA library subcloned into the
prey vector, pACT2, was purchased from Clontech. The yeast strain
L40, harboring the reporter genes lacZ and HIS3 downstream of the
LexA promoter, was sequentially transformed with bait vector followed
by cDNA library vectors and then plated on a synthetic medium con-
taining 5 mM 3-amino-1,2,4-triazole and lacking histidine, leucine, and
tryptophan residues. After incubating the plates for 10–14 days at 30 °C,
the transformants were tested with a synthetic medium that lacked
histidine, leucine, and tryptophan residues and contained 50 g/ml
5-bromo-4-chloro-3-indoryl-D-galactoside. After incubation for 2–3
days at 30 °C, the blue yeast colonies were selected as positive clones.
The positive clone plasmids were extracted from yeast in lysis buffer
containing 2%TritonX-100, 1% SDS, 100mMNaCl, 10mMTris, pH 8.0,
and 1.0 mM EDTA and then transformed into E. coli DH5 via electro-
poration. Sequences of the inserts in positive library plasmids were ana-
lyzed with an automatic DNA sequencer (ALF express, Amersham
Biosciences).
Cell Culture and Preparation of Cell Lysates—Human embryonic
kidney 293 (HEK293) cells and dopaminergic neuroblastoma SH-SY5Y
cells were maintained in Dulbecco’s modified Eagle’s medium contain-
ing 10% fetal bovine serum and 100 units/ml penicillin/streptomycin.
To prepare cell lysates, the cells were rinsed twice with ice-cold phos-
phate-buffered saline and solubilized in lysis buffer (20mMTris, pH 7.9,
containing 1.0% Triton X-100, 1 mM Na3VO4, 137 mM NaCl, 1 g/ml
leupeptin, 1 g/ml aprotinin, 1 mM sodium orthovanadate, 1 mM
EGTA, 10mMNaF, 1mM tetrasodiumpyrophosphate, 5mMNa2EDTA,
10% glycerol, 1 mM -glycerophosphate, 0.1 g/ml p-nitrophenyl phos-
phate, and 0.2 mM phenylmethylsulfonyl fluoride). The cells were
scraped, and the supernatants were collected after 10 min of centrifu-
gation at 14,000 g and 4 °C. Protein concentrations were determined
using the detergent-compatible protein assay kit (Bio Rad).
Immunoprecipitation andWestern Blot Analysis—Onemicrogramof
antibodies was incubated with 1 mg of cell extracts prepared in lysis
buffer overnight at 4 °C. Thirtymicroliters of a 1:1 suspension of protein
A-Sepharose beads was added and incubated for 2 h at 4 °C with gentle
rotation. The beads were pelleted and washed five times with cell lysis
buffer. Bound proteins were dissociated by boiling in SDS-PAGE sam-
ple buffer, andwhole protein samples were separated on SDS-polyacryl-
amide gel, and then transferred to a nitrocellulose membrane (Milli-
pore, Japan). The membrane was blocked in TBST buffer containing 20
mMTris, pH 7.6, 137mMNaCl, 0.05%Tween 20, and 5%nonfat drymilk
for 1 h and then incubated overnight at 4 °C in 3% nonfat dry milk
containing antibodies. The membrane was washed several times in
TBST, and then incubated with secondary IgG-coupled horseradish
peroxidase antibody (Zymed Laboratories Inc.). After 60 min, blots
were washed several times with TBST and were visualized by ECL.
RNA Interference—The matched and nonsilencing siRNAs of
RanBP2 were generated as described previously (22). The target cells
were transfected with the annealed double-strand RNA oligonucleo-
tides (PROLIGO Primer & Probes, Boulder, CO) using Lipofectamine
(Invitrogen) at a final concentration of 100 nM.
In Vitro Ubiquitination Assay—Fifty microliters of in vitro ubiquiti-
nation reaction contained reaction buffer (50 mM Tris-HCl, pH 7.6, 5
mM MgCl2, 2 mM ATP, 2 mM dithiothreitol), 10 g of recombinant
ubiquitin, 100 ng of E1 (Calbiochem), 200 ng ofUbcH7 (Sigma), and 500
ng of GST-IR as a substrate. The reaction was performed via the addi-
tion of either Myc-tagged Parkin or its deleted mutants produced by
TNT quick-coupled transcription/translation systems (Promega) for 2 h
at 37 °C and terminated by mixing with an equal volume of 2 SDS
sample buffer. The reaction products were subjected to Western blot
analysis and were analyzed with anti-GST or anti-ubiquitin antibodies
(Santa Cruz Biotechnology).
RESULTS
Yeast Two-hybrid Assay for the Identification of New Parkin E3 Ubiq-
uitin Ligase Substrate(s)—To identify the new Parkin-binding part-
ner(s), we performed yeast two-hybrid assay by using full-length wild
type Parkin as bait. After screening human fetal brain cDNA library,
several previously known and novel proteins were identified to interact
with Parkin, including cyclin E, -tubulin, and RanBP2 (data not
shown). Among these, RanBP2 is a component of cytoplasmic filaments
in the nuclear pore complex (23). Nuclear pore complex traverses the
nuclear envelope, providing a channel through which nucleocytoplas-
mic transport occurs. RanBP2 is thought to play an important role in
CRM1-mediated nuclear protein export (24). In addition, RanBP2 is
known to function as a SUMO E3 ligase (25). To determine whether
RanBP2might be a new ubiquitination target of Parkin, and/or whether
the potential binding between these two proteins might alter the func-
tional activity of Parkin, RanBP2 was chosen as a target for further
analysis.
Parkin Interacts with RanBP2 in Vivo and in Vitro—First, we
attempted to determine whether Parkin selectively binds to RanBP2 in
mammalian cells. After eukaryotic expression plasmid encoding FLAG-
tagged humanwild type Parkinwas transiently transfected intoHEK293
cells, and the cell lysates were prepared, immunoprecipitated with anti-
RanBP2 antibodies, and subsequently immunoblotted with anti-FLAG
IgG. As shown in Fig. 1A, the transfected FLAG-tagged Parkin was able
to bind to endogenous RanBP2 in the HEK293 cells. When co-immu-
noprecipitation was performed in reverse with anti-FLAG antibodies,
followed by immunoblot analysis with anti-RanBP2 IgGs, the results
was the same. This indicates that FLAG-Parkin binds well to RanBP2
(Fig. 1A). We next examined whether this specific association between
Parkin andRanBP2was also present in humandopaminergic neuroblas-
toma (SH-SY5Y) cell lines. After eukaryotic expression plasmid encod-
ing FLAG-tagged Parkin was transfected into the SH-SY5Y cells (Fig.
1B), the immunoprecipitation was performed with either anti-RanBP2
or anti-FLAGantibodies. As shown in Fig. 1B, Parkin selectively binds to
endogenous RanBP2. When the same co-immunoprecipitation assay
was performed in the neuroblastoma SK-N-BE2C cell line, the specific
interaction between RanBP2 and Parkin was also observed (data not
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shown). These results suggest that the specific binding of Parkin to
RanBP2 occurs in mammalian cells.
To characterize further the interactions between Parkin and RanBP2,
SH-SY5Y cells were cultured on glass coverslips and transfected with
GFP-Parkin. The expression of GFP-Parkin proteins was visualized by
using a confocal microscope. Immunofluorescence analysis of endoge-
nous RanBP2 was carried out with anti-RanBP2 IgG and then rhodam-
ine-conjugated secondary antibodies. As shown in Fig. 2C, the co-local-
ization of RanBP2 and GFP-Parkin was observed (Fig. 1C).
To confirm the specific interaction between Parkin and RanBP2 and
to identify the interaction site, an in vitro GST pull-down assay was
performed by using recombinant GST-Parkin fusion protein (Fig. 1D).
To confirm the proper expression and purification of GST-Parkin and
its mutants, Western blotting was performed with anti-GST IgG and
two anti-Parkin antibodies; one is specific for amino acid residues 83–97
of the human Parkin N terminus, and the other is specific for several
residues around the C-terminal 400th amino acid of Parkin. After
HEK293 cell extracts were incubated with GST fused either with wild
type Parkin or its deleted mutants (amino acids 77–465 or 1–170),
immunoprecipitation was carried out with anti-RanBP2 antibodies, fol-
lowed by immunoblot analysis with either anti-GST antibodies. As
shown in Fig. 1D, both wild type and deleted mutant Parkin fused with
GST were co-immunoprecipitated with endogenous RanBP2. When
used as a negative control, GST alone was determined not to interact
with RanBP2. The Parkin fragment spanning its 78–170th amino acid
fused with GST was shown to interact with RanBP2 (Fig. 1E). In addi-
tion, an excess amount of GST-Parkin peptide (amino acids 78–170)
blocked the binding of RanBP2 to Parkin (Fig. 1E). These data indicated
that Parkin directly binds to RanBP2 in vitro as well as in vivo, and the
region spanning amino acid residues 78–170 appears to be important
for its binding to RanBP2.
We next attempted to determine whether the specific association
between Parkin and RanBP2, which had been encountered in both in
vitro and in cell-based assays, was also present in mammalian neural
tissues of the central nervous system. After the rat and mouse brain
cortex were isolated and homogenized, Western blot analysis revealed
that significant levels of Parkin are present (Fig. 1F, left). The cell
extracts were then immunoprecipitated with anti-RanBP2 antibodies,
followed by the immunoblot analysis with either anti-Parkin or anti-
RanBP2 antibodies. As shown in Fig. 1F, Parkin selectively associated
proper expression of transient-transfected and endogenous proteins in cell lysates was
also identified, as described in A. C, SH-SY5Y cells were transfected with plasmids for
GFP-tagged Parkin (P). After 24 h of incubation, the cells were fixed, permeabilized, and
labeled with anti-RanBP2 antibodies (R), followed by staining with nuclear marker,
anti-Rb (Rb) IgG, or rhodamine-attached secondary antibodies, and stained with DAPI
(D). Immunostainedpreparationswere examinedwith confocalmicroscopy.Arrowheads
indicate the expression of RanBP2 and Parkin. M indicates the “merge” of the P and R
images. D, in the left and right panels, immunoblots with either anti-GST or anti-Parkin
(two antibodies specific to the N-terminal or C-terminal region, respectively) antibodies
validated the expression of recombinant GST-Parkin and its deletedmutants constructs
used for the in vitro binding assay. In themiddle panel, after the HEK293 cell extract was
incubated with the purified recombinant GST-fused wild type Parkin (PRK) or its deleted
mutants (MT1, residues 77–465; MT2, residues 1–170) or GST as a control, immunopre-
cipitation was performed with anti-RanBP2 antibodies, and the precipitated protein
complexes were analyzed by Western blotting with anti-GST antibodies. E, HEK293 cell
extracts were incubated with the recombinant GST-fused Parkin peptide, which spans
78–180aminoacids (P) orGSTalone (G) as a control, in the absenceorpresenceof 100nM
blockingpeptide (I); immunoprecipitationwasperformedwith anti-RanBP2, followedby
Western blotting with anti-GST antibodies. The presence of GST-Parkin or GST in the
complexes was examined by using anti-GST or anti-Parkin antibodies, as indicated. F,
after themouse (M) and rat (R) brain cortexwere isolated, cell lysateswere preparedwith
gentle homogenization. Where indicated, the immunoprecipitation of the cortical cell
lysates was done with either preimmune IgG or anti-RanBP2 antibodies (R) and immu-
noprecipitates were analyzed via Western blot analysis with anti-RanBP2 or anti-Parkin
antibodies (PRK). The proper expression of Parkin in cortical cell extracts was identified
by the immunoblotting with anti-Parkin antibodies (right panel).
FIGURE 1. Parkin interacts with endogenous RanBP2 both in vivo and in vitro. A,
where specified, HEK293 cell lines were mock-transfected (C) or transfected with plas-
mids for FLAG-tagged wild type Parkin (PRK) in a transient manner. After 24 h, immuno-
precipitation (IP) was performed with either anti-RanBP2 or anti-FLAG antibodies, as
indicated. The immunocomplexes were then resolved by SDS-PAGE and analyzed by
Western blotting with anti-FLAG or anti-RanBP2 antibodies. The proper expression of
transient-transfected and endogenous proteins in cell lysates was identified with West-
ern blot analysis with anti-FLAG or anti-RanBP2 antibodies. B,where specified, SH-SY5Y
cells were transfectedwith 3gof plasmid encoding FLAG-taggedwild type Parkin (PRK
or P). The cells were immunoprecipitated with preimmune IgG, anti-RanBP2, or anti-
FLAG antibodies, followedby immunoblot analysis with anti-FLAG IgG, as indicated. The
RanBP2 Is a Target of Parkin Ubiquitin E3 Ligase
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with RanBP2. As a control, the analysis of immunocomplexes prepared
with preimmune IgG revealed that there is no obvious Parkin band for
interactionwith RanBP2 (Fig. 1F). The same interaction between Parkin
and RanBP2 was also observed in the extracts from other brain tissues,
such as the hippocampus and midbrain (data not shown).
Parkin Interacts with the IR1  2 Domain of RanBP2—To verify
further this binding and tomap the binding domain within the RanBP2,
plasmids encoding for FLAG-tagged Parkin were co-transfected into
HEK293 cells with a construct designed for the expression of GFP-
tagged RanBP2 deletionmutant (IR1 2), spanning amino acids 2633–
2761 of RanBP2, followed by immunoprecipitation with either anti-
FLAG or anti-GFP antibodies, respectively. The IR1  2 region was
shown previously to bind to the SUMO-conjugating E2 enzyme, Ubc9,
and to possess the SUMO-E3 ligase activity of RanBP2 (25–27). As
shown in Fig. 2A, Western blot analysis of the immunocomplexes with
either anti-GFP or anti-FLAG antibodies demonstrated that Parkin
binds to IR1 2. In addition, the incubation of excess recombinant IR1
 2 proteins, as a blocking peptide, resulted in the inhibition of Parkin
binding to IR1 2 (Fig. 2A). Furthermore, when the plasmid encoding
unrelated FLAG-GAdd45 or intactGFPwas used as a negative control,
they did not bind to GFP-IR1  2 or FLAG-Parkin, respectively (Fig.
2B). The binding between Parkin and IR1 2 domainwas also observed
in murine dopaminergic MN9D cells (Fig. 2C). In addition, the immu-
nohistochemical analysis was performed to examine whether Parkin is
co-localizedwith IR1 2. After SH-SY5Y cells were co-transfectedwith
plasmids encoding forMyc-tagged Parkin plus GFP-tagged IR1 2, the
cells were labeled with anti-Parkin antibodies, followed by staining with
rhodamine-attached secondary antibodies. As shown in Fig. 2C, fluo-
rescence microscopic observation indicated that the localization of IR1
 2 expression is coincident with that of Parkin within the nucleus.
These data indicate that IR1 2 domain of RanBP2 specifically interacts
with Parkin.
Parkin Promotes the Ubiquitination of RanBP2 and Its Degradation
via Ubiquitin-Proteasome System (UPS) Pathway—To determine the
functional relevance of the mutual interaction between Parkin and
RanBP2, we attempted to ascertain whether RanBP2 could function as a
substrate of Parkin E3 ubiquitin ligase. To evaluate whether Parkin
couldmediate the degradation of RanBP2 via theUPS,we firstmeasured
the effects of Parkin overexpression on the endogenous levels of
RanBP2. After the transient transfection of plasmid encoding for FLAG-
Parkin into HEK293 cells, cell lysates were prepared, and Western blot
analysis was performed with anti-RanBP2 or anti-FLAG antibodies. As
shown in Fig. 3A, Parkin was properly expressed inside the cells after its
transient transfection, and a significant decrease in RanBP2 protein lev-
els was detected after 48 h in the cells exhibiting Parkin overexpression,
as compared with control cells transfected with vehicle only (Fig. 3A,
right). These findings suggest that Parkin may either promote the deg-
radation of and/or block the synthesis of RanBP2. To ensure that this
Parkin-mediated reduction in endogenous RanBP2 levels was not an
event specific to the HEK293 cells, the same experiment was conducted
in SH-SY5Y cells and H19-7 cells. Just as seen in the HEK293 cells, the
endogenous RanBP2 protein levels also decreased after 36 and 48 h of
post-transfection with Parkin plasmid in the SH-SY5Y cells (Fig. 3A,
left) and H19-7 cells (data not shown), indicating that Parkin overex-
pression results in the down-regulation of intracellular RanBP2.
In addition, we tested whether the dominant-negative Parkin mutant
containing the 77–465-amino acid domain affects the Parkin-mediated
reduction in RanBP2 levels. When the plasmid encoding the function-
ally defective Parkin mutant was transfected into SH-SY5Y cells, the
endogenous RanBP2 levels were not significantly changed, as compared
with mock-transfected cells (Fig. 3B). Therefore, this result indicated
that the E3 ubiquitin ligase activity of Parkin was required for the reduc-
tion of endogenous RanBP2 levels.
To determine whether Parkin-mediated RanBP2 degradation
occurred via the UPS pathway, the endogenous levels of RanBP2 in the
cells transiently transfected with FLAG-Parkin were measured and
compared in the absence or presence of clasto-lactacystin -lactone
(lactacystin), the highly specific proteasomal proteolysis inhibitor.
Based on our previous report (17), in which Parkin was shown to cleave
intracellular-synuclein inclusions via calpain activation, we also tested
the effect of the calpain inhibitor, calpeptin, to confirm the involvement
of calpain in the Parkin-mediated degradation of RanBP2. When
SH-SY5Y cells were transiently transfected with Parkin, followed by the
stimulation of lactacystin, the reduction of endogenous RanBP2 levels
was remarkably blocked, as compared with the control cells that were
FIGURE 2. Parkin interacts with IR1  2, the deletion mutant of RanBP2. A, where
indicated, 3 g of plasmid encoding for either FLAG-tagged whole Parkin (P) or GFP-
tagged deleted RanBP2 mutants (IR1  2 or denoted as I) were transfected, or two
plasmids were co-transfected into HEK293 cells (IP) in the absence or presence of 100
nM recombinant GST-IR1  2 (B) as a blocking peptide. Immunoprecipitation (IP) was
performed with either anti-FLAG or anti-GFP antibodies, and the immunocomplexes
(upper panel) and cell lysates (lower panel) were analyzed byWestern blotting with anti-
GFP or anti-FLAG antibodies, as indicated. B,where specified, the cells were transfected
with GFP alone (G), GFP plus FLAG-Parkin (G P; left panel), GFP-IR1 2 (I), or GFP-IP1
2 plus FLAG-Gadd45 (I F; right panel). The cells were immunoprecipitated with anti-
FLAG or anti-GFP antibodies, followed by the immunoblot analysis with anti-GFP or
anti-FLAG antibodies, as indicated. The proper expression of transiently transfected pro-
teins in cell lysates was analyzed with anti-GFP or anti-FLAG antibodies. C,where speci-
fied, dopaminergic MN9D cells were transfected with 3 g of mammalian plasmid
encoding GFP-tagged IR1 2mutant of RanBP2 (IR) or co-transfectedwith FLAG-Parkin
plusGFP-IR12 (IRP), as indicated. The cellswere immunoprecipitatedwith anti-FLAG
antibodies, followed by immunoblot analysis with anti-GFP IgG. The proper expression
of transiently transfected proteins in cell extracts was examined withWestern blot anal-
ysis with either anti-FLAG or anti-GFP antibodies.D,where specified, SH-SY5Y cells were
co-transfected with plasmids encoding for FLAG-tagged Parkin (P) plus GFP-tagged IR1
 2 (I). After 24 h of incubation, the cells were fixed, permeabilized, and labeled with
anti-Parkin antibodies, followed by staining with rhodamine-attached secondary anti-
bodies, and stained with DAPI (D).M indicates the “merge” of the P and I images. Immu-
nostained preparations were examined with fluorescence microscopy.
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not treated with lactacystin. In contrast, we witnessed no significant
effects on the recovery of the reduced RanBP2 levels as a result of pre-
treatment with calpeptin (Fig. 3C). These results indicated that Parkin
promotes RanBP2 degradation, which appears to be mediated some-
what by the activation of proteasome-dependent proteolyticmachinery,
but not through calpain activation. Moreover, the same results were
FIGURE 3. Parkin-induced degradation of
RanBP2 occurs through UPS system. A, after
either HEK293 (left) or SH-SY5Y cells (right) were
mock-transfected (C) or transiently transfected
with 3 g of plasmid encoding for FLAG-tagged
wild type Parkin (P) for the indicated times, the
cells were lysed, and the cell extracts were
resolvedby SDS-PAGE and then analyzedbyWest-
ern blotting with either anti-RanBP2 or anti-FLAG
antibodies, as indicated. The graphs indicate the
intensity of the bands using the densitometric
analysis (Image 3.1 program from the National
Institutes of Health). To confirm the equal loading
of protein, the level of -tubulin in each lane was
determined as a control. B, after the SH-SY5Y cells
were mock-transfected (C) or transfected with
plasmids encoding for Myc-tagged wild type Par-
kin (WT) or its deleted mutant (amino acids
77–465; MT) for 48 h, the cell extracts were
resolvedby SDS-PAGE and then analyzedbyWest-
ern blotting with either anti-RanBP2 or anti-Myc
antibodies (WT-PRK or MT-PRK), as indicated. The
graph indicating the intensity of the bands is
expressed as in Fig. 3A. Data are presented as
means  S.E. of three independent experiments
conducted in triplicate. *, p  0.05. C, after the
SH-SY5Y cells were mock-transfected (C) or trans-
fected with 3 g of plasmid encoding for FLAG-
tagged Parkin, the cells were untreated (No T) or
treated with either 10 M proteasome inhibitor,
clasto-lactacystin -lactone (Lac), 50 M calpeptin
(CPT), 10 M MG132 (MG), or 200 nM epoxomicin
(Epx) for 6 h, as indicated. Total cell lysates were
resolved by SDS-PAGE and analyzed by Western
blotting with anti-RanBP2 or anti-FLAG antibod-
ies, as indicated. The graphs indicated the inten-
sity of the bands, quantitated as in A.
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observed in the cells treated with other proteasome inhibitors, such as
MG132 and epoxomycin (Fig. 3C).
The observation that RanBP2 expressed in cultured cells is liable to be
digested through the proteasomal system and its degradation is facili-
tated by Parkin prompted us to examine whether RanBP2 can be
covalently modified by ubiquitin via the action of Parkin. After HEK293
cells were transfected with eukaryotic expression plasmids for either
FLAG-tagged ubiquitin plus GFP-tagged IR1 2 alone or together with
Myc-Parkin as indicated, the cells were untreated or treated with lacta-
cystin. The cell lysates were immunoprecipitated with anti-FLAG or
anti-GFP antibodies, followed by immunoblot analysis with anti-GFP or
anti-FLAG IgG. As shown in Fig. 4, the pretreatment of lactacystin
accelerated the ubiquitination of IR1  2 in the cells transfected with
Parkin, compared with control cells. These results indicated that
RanBP2 becomes a target of Parkin E3 ubiquitin ligase, and its levels are
regulated by Parkin and the proteasomal complex system.
Parkin Ubiquitinates RanBP2 in Vitro—Using in vitro ubiquitination
assay, we attempted to determine whether Parkin could directly ubiq-
uitinate RanBP2. To reconstitute the ubiquitin-conjugation-ligation
reaction, in vitro translated wild type Parkin or its deleted mutants
(amino acids 77–465, 1–415, and 217–465) were added to reaction
mixtures containing recombinant ubiquitin, E1, and E2. It has been
reported that the E3 ubiquitin ligase activity of these mutants is absent
(11). Because the intact RanBP2 is too large (358 kDa) to detect further
processing, such as into polyubiquitination, the recombinant-deletion
RanBP2 mutant fused with GST (GST-RanBP2-IR), spanning amino
acids 2596–2836 of RanBP2 and possessing the full SUMO-E3 ligase
activity (26, 27), was used as a potential substrate in an in vitro ubiquiti-
nation assay. Western blot analysis with anti-Parkin antibodies demon-
strated that the synthesis of Parkin proteins and its mutants properly
occurs by TNT in vitro translation (Fig. 5).
As shown in Fig. 5, in order to ascertain whether wild type Parkin
promotes the ubiquitination of RanBP2-IR, the reaction samples were
immunoanalyzed with anti-ubiquitin antibodies. When compared with
the samples prepared in the absence of Parkin or in the presence of its
deleted mutant, the samples added with wild type Parkin exhibited sig-
nificant increases in ubiquitinated protein bands, thereby indicating
that Parkin functions as an E3 ubiquitin ligase and enhances protein
ubiquitination. The analysis of reaction sampleswith anti-GST antibod-
ies confirmed that the addition of in vitro translated wild type Parkin
proteins promotes the ubiquitination of RanBP2 more profoundly than
does the fraction containing in vitro translated control vector or in vitro
translated Parkin mutants (Fig. 5). These data strongly suggest that the
high molecular weight ubiquitinated proteins represent the ubiquiti-
nated RanBP2-IR, and Parkin is able to ubiquitinate RanBP2 directly in
vitro.
Parkin Controls the Intracellular Levels of Sumoylated HDAC4 as a
Result of theUbiquitination andDegradation of RanBP2—Nextwe tried
to determine how Parkin functionally affects intracellular metabolic
activities as a result of RanBP2-ubiquitination and its consequent deg-
radation. Based on the previous findings that two target proteins, SP100
(27) and HDAC4 (26), are known to be sumoylated by RanBP2, it was
FIGURE 4. Parkin promotes the ubiquitination of IR1  2-RanBP2 in vivo. After
HEK293 cellswere transfectedwith theplasmids for either FLAG-taggedubiquitin (FLAG-
Ub) and GFP-tagged IR1  2 or together with Myc-tagged Parkin (Myc-PRK), the cells
were incubated in the absence or presence of 10M clasto-lactacystin-lactone (Lac) for
6 h. The cell lysateswere immunoprecipitated (IP) with anti-FLAGor anti-GFP antibodies,
followed by immunoblot analysis with anti-GFP or anti-FLAG antibodies. To determine
the proper expression of GFP-IR1  2, Myc-Parkin and FLAG-ubiquitin, Western blot
analysis of the cell lysates was performedwith anti-GFP, anti-Myc, or anti-FLAG antibod-
ies, as indicated. The intact IR1 2,Myc-Parkin (PRK), FLAG-ubiquitin (Ub), and immuno-
globulin heavy chain (H.C.) are denoted by arrowheads.
FIGURE 5. Parkin ubiquitinates RanBP2 in vitro.Where indicated, either recombinant
deleted IR-RanBP2protein fusedwithGST (GST-IR) orGSTas a controlwas incubatedwith
an in vitro ubiquitination system, which contains recombinant Ub, E1, and E2. As the
source of E3 ubiquitin ligase, wild type Parkin (Wt) or its deleted mutants (M1, 77–465;
M2, 1–415; and M3, 217–465) produced using TNT in vitro transcription/translation kit
was added to the reaction assay. The formation of ubiquitinated reaction products was
evaluated by Western blot analysis with either anti-ubiquitin or anti-GST antibodies. To
confirm the proper expression and purification of Parkin and its mutants and GST-IR,
Western blot analysis was performedwith anti-Parkin antibodies or anti-GST antibodies.
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examined whether Parkin was able to modulate intracellular levels of
sumoylated HDAC4 in either a direct or an indirect way. HDACs mod-
ulate cell growth and differentiation by governing chromatin structure
and repressing the activity of specific transcription factors. First, to ver-
ify the SUMO modification of HDAC4, the HEK293 cells were tran-
siently transfected with plasmids encoding for either FLAG-tagged
HDAC4 alone or together with SUMO-1 construct. As shown in Fig.
6A, the FLAG-taggedHDAC4 proteins were significantly sumoylated in
the presence of SUMO-1. Second, we attempted to determine whether
the amount of sumoylated HDAC4 could be altered by Parkin overex-
pression. After the HEK293 cells were transiently transfected with
eitherHA-tagged SUMO-1plus FLAG-taggedHDAC4or togetherwith
wild type Parkin plasmid or the deleted form of Parkin (amino acids
77–465), the sumoylated HDAC4 levels were compared by the immu-
noprecipitation with anti-HA, followed by immunoblotting with anti-
FLAG antibodies. As shown in Fig. 6A, the levels of sumoylatedHDAC4
were diminished completely in the cells transfected with wild type Par-
kin, but there was amarked enrichment of sumoylatedHDAC4 levels in
the cells transfected with the deleted Parkin mutant. In addition, when
the plasmid encoding antisense Parkin was co-transfected into the cells
to block the Parkin expression (50), the reduced level of sumoylated
HDAC4 was also remarkably enhanced (Fig. 6B). However, the
co-transfection of Parkin with either sense or antisense Nedd4-2, as a
control of unrelated protein, did not affect the Parkin-mediated inhibi-
tion of the mutual interaction between HDAC4 and SUMO-1 (Fig. 6B).
To determine whether Parkin directly interacts with HDAC4, a eukary-
otic expression plasmid for GFP-tagged HDAC4 was transiently co-
transfected intoHEK293 cells with FLAG-Parkin, followed by immuno-
precipitation with either anti-GFP or anti-FLAG antibodies (Fig. 6C).
When the immunocomplexes were resolved by SDS-PAGE, and ana-
lyzed using anti-FLAG or anti-GFP antibodies, respectively, Parkin was
demonstrated to bind to HDAC4. This Parkin/HDAC4 interaction
might occur via directmutual interaction and/or indirect interaction via
RanBP2 linking. To distinguish between these two possibilities, in vitro
binding assays were conducted followed by Western blot analysis or
autoradiography using recombinant GST-Parkin and in vitro translated
HDAC4 proteins. As shown in Fig. 7A, wild type Parkin did not interact
directly with HDAC4 in vitro. To confirm this finding further, the
siRNA of RanBP2 was transfected into the cells to reduce intracellular
RanBP2 levels, and it was then determinedwhether the binding between
Parkin and HDAC4 still occurred. As shown in Fig. 7B, the knock down
of endogenous RanBP2 levels, which was induced by its siRNA, resulted
in the abrogation of Parkin binding to HDAC4, whereas there was no
effect by using the nonsilencing mismatched siRNAs (Fig. 7C). These
data indicated that the interaction between Parkin and HDAC4 in the
Parkin immunocomplexesmight be indirectly possible throughRanBP2
linking. Taken together, our data suggest that, as a result of RanBP2
ubiquitination, Parkin could also control the intracellular levels of
sumoylated HDAC4, the sumoylation target of RanBP2.
DISCUSSION
Parkin is the causative gene of early onset AR-JP (6). As the Parkin
gene product functions as an E3 ubiquitin ligase (10, 11, 13), it has been
hypothesized that the functional loss of Parkin because of themutations
or deletions at the gene level results in a gradual accumulation of its
substrates, eventually leading to the cell death within the substantia
nigral neurons. In this study, we performed a yeast two-hybrid assay to
identify additional potential factors or substrates that are involved in
PD. As a result of screening, RanBP2 was observed to interact specifi-
cally with Parkin. As RanBP2 has been reported to play a role as an E3
SUMO ligase, it could be speculated that the SUMO-E3 ligase activity of
RanBP2 might be modulated by Parkin and/or Parkin might be sumoy-
lated by RanBP2.
Additional co-immunoprecipitation binding assays confirmed that
RanBP2 physically interacts with Parkin in mammalian cells. In addi-
tion, it was found that Parkin ubiquitinates RanBP2 in vitro and pro-
motes the degradation of RanBP2 via UPS in HEK293 and SH-SY5Y
cells. Our current findings suggest that the functional activity of RanBP2
FIGURE 6. Parkin controls intracellular levels of sumoylated HDAC4 through the
indirect degradation of RanBP2. A,where specified HEK293 cells were co-transfected
with two plasmids of HA-tagged SUMO-1 (SU) and FLAG-tagged HDAC4 (H) and/or with
either Myc-tagged wild type Parkin vector (WT) or its deleted mutant (amino acids
77–465;MT), followed by immunoprecipitation (IP) with anti-HA IgG. Then the immuno-
complexes were resolved by SDS-PAGE and analyzed using anti-FLAG IgG. The expres-
sion of transfected target proteins in the cell lysateswas identifiedwith immunoblotting
with anti-HA, anti-FLAG, or anti-Myc antibodies.B,HEK293 cellswere co-transfectedwith
HA-SUMO-1 (SU) and FLAG-HDAC4 (H) and/orwithMyc-taggedwild type Parkin (PRK), as
indicated. Where specified, the cells were co-transfected together with the plasmid
encoding antisense Parkin (AS-PRK), sense (SS-Nedd), or antisense His-tagged Nedd4–2
(AS-Nedd), followed by immunoprecipitation with anti-HA IgG. Then the immunocom-
plexes were resolved by SDS-PAGE and analyzed using anti-FLAG IgG. The expression of
transfected target proteins in the cell lysates was identified with immunoblotting with
anti-Mycor anti-His antibodies.C, as indicated, 3gof plasmid encoding forGFP-tagged
HDAC4 (H) were co-transfected with FLAG-tagged Parkin plasmid (P) into HEK293 cells.
Immunoprecipitation (IP) was performed with anti-FLAG or anti-GFP antibodies, and
immunoprecipitateswere analyzedbyWestern blottingwith anti-GFPor anti-FLAGanti-
bodies, as indicated. “C” in A and C indicates “control.”
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SUMO-E3 ligase may be regulated by Parkin-mediated ubiquitination
and subsequent proteasomal degradation.
Among several Parkin substrates are transmembrane proteins or
membrane-associated proteins. They are ubiquitinated by Parkin and
subsequently degraded through the proteasome, which finally leads to
the down-regulation of their activities. For instance, newly synthesized
Pael-R is folded into the endoplasmic reticulum (ER) and then trans-
ported to the cell membrane.Misfolded Pael-R is normally translocated
across the ER membrane into the cytosol, ubiquitinated by Parkin, and
then degraded through the proteasome pathway (15). However, exces-
sive amounts of unfolded Pael-R in the ER cause ER stress and finally
leads to cell death. Parkin inhibits ER stress-mediated cell death by
ubiquitinating and enhancing the degradation of unfolded Pael-R (10,
15). In addition, Parkin ubiquitinates and promotes the degradation of
misfolded dopamine transporter (DAT). Parkin increases dopamine
uptake by enhancing the ubiquitination and degradation of misfolded
DAT, in order to prevent it from interfering with the oligomerization
and cell surface expression of native DAT (28). Furthermore, Parkin
promotes the degradation of synaptic-vesicle-associated CDCrel-1,
which is localized mainly to presynaptic axon terminals of inhibitory
neurons (13). This study reveals that the nuclear membrane-associated
RanBP2 is subject to the ubiquitination and subsequent degradation via
Parkin and proteasomal machinery, and Parkin could affect the nucle-
ocytoplasmic protein transport in some way.
To date, two major forms of multiubiquitin chains are known to be
formed through distinct types of linkages, in which the isopeptide bond
linkages involve Lys-48 or Lys-63. Lys-48-linked ubiquitin tagging is
mostly used to target proteins for degradation by the proteasome,
whereas Lys-63-linked ubiquitination has been linked to numerous cel-
lular events that do not rely on the degradative signaling via the protea-
some. Of these, the endocytosis of membrane proteins (41–44), protein
sorting and trafficking (45–47), and post-replicative DNA repair (48)
are well characterized. Doss-Pepe et al. (49) have reported recently that
Parkin has dual specificity for the assembly of ubiquitin chains through
two different linkages to the substrate (Ub-Lys-48 and Ub-Lys-63).
Based on the current finding that Parkin promotes the degradation of
RanBP2 via UPS, Ub-Lys-48 is thought to be involved in its linkage to
RanBP2.
Histone acetylation promotes gene transcription by relaxing chroma-
tin structure, thereby facilitating access of the transcriptional machin-
ery to DNA target sequences. The transcription-activating effect of his-
tone acetylation is counterbalanced by histone deacetylation, which
favors chromatin condensation and transcriptional repression. There
are two major classes of HDACs (29). The class I HDACs (HDAC1–3
and 8) are widely expressed and consist mainly of a catalytic domain. In
contrast, the class II HDACs (HDAC4, -5, -7, and -9) display cell type-
restricted patterns of expression and contain an N-terminal extension
that links them to specific transcription factors and confers responsive-
ness to a variety of signal transduction pathways, thereby connecting the
genome with the extracellular environment (30). Class II HDACs inter-
vene in cell differentiation, particularly in muscle (31–33). Most inter-
estingly, all known class II proteins can shuttle from the cytoplasm to
the nucleus, whereas most class I HDACs are constitutively present
within the nucleus (34).
HDAC4 shows the highest expression in heart, skeletal muscle, and
brain (35–37). HDAC4 is also known to interact with the MEF2 family,
well known transcriptional activators playing roles in myogenesis and
inhibit muscle differentiation (31, 37–39). Most interestingly, this tran-
scription-repressing ability and histone deacetylase activity of the
sumoylation-deficient HDAC4 mutant was impaired when compared
with that of the wild-type HDAC4 protein (26). Although HDAC4 is
part of large multiprotein complexes that mediate its recruitment to
specific promoters (30), little is known about how its expression and
stability are regulated. Recently, caspases are reported to modulate spe-
cifically gene repression and apoptosis through the proteolytic process-
ing of HDAC4 (40). The current finding shows that Parkin could mod-
ulate the intracellular levels of sumoylated HDAC4 which is known to
bemodified by RanBP2 (26). Thismight have an implication that Parkin
could play a role during the process of muscle differentiation. Further-
more, it may be predicted that the abrogation of Parkin function caused
by gene level mutations, and seen in AR-JP, negatively affects proper
RanBP2 degradation, and the abnormal accumulation of RanBP2might
consequently contribute to the formation of abnormal protein inclu-
sions and the pathogenesis of PD. It will be also very interesting to find
outwhether Lewy bodies, which are typically found in the dopaminergic
neurons of the substantia nigra in PD patients, also include RanBP2.
In conclusion, this study has provided valuable evidence that RanBP2
is a new substrate of Parkin, and Parkin can modulate the enzymatic
activity of RanBP2 by ubiquitination and subsequent degradation. Our
FIGURE 7. Parkin did not bind directly to HDAC4 in vitro. A, after in vitro translated
FLAG-tagged HDAC4 using the TNT transcription/translation kit was incubated with the
indicated recombinant GST fused with either wild type Parkin (P) or its deleted mutants
(M1, 77–465;M2, 1–170), or GST alone as a control, we performed aGSTpull-down assay.
The precipitated protein complexes were then analyzed by Western blotting with anti-
FLAGantibodies (left) or by autoradiography (right). The last lane in eachpanel shows the
proper expression and purification of FLAG-HDAC4 as an input. B, as indicated, HEK293
cells weremock-transfected (C) or transfectedwith plasmid encoding FLAG-Parkin (P) or
GFP-HDAC (H), respectively. Where specified, the cells were co-transfected with GFP-
HDAC4 and FLAG-Parkin (PH) in the absence or presence of siRNA of RanBP2 (100 nM).
After 72 h, immunoprecipitation (IP) was performedwith anti-FLAG antibodies, followed
by Western blot analysis with anti-GFP IgG. Western blot analysis was carried out with
anti-RanBP2, anti-FLAG,or anti-GFPantibodies to identify theproper expressionof trans-
fected or endogenous RanBP2 in the cell lysates. C, in the same way as B, HEK293 cells
were transfected with suitable plasmids, as indicated. Where specified, the cells were
co-transfected with the 100 nM siRNA-RanBP2 (si-R) or its mismatched RNA (NS). After
72 h, immunoprecipitationwas performedwith anti-FLAGantibodies, followedbyWest-
ern blot analysis with anti-GFP or FLAG IgGs. Western blot analysis was carried out with
anti-RanBP2 or anti-GFP antibodies to identify the proper expression of RanBP2 or GFP-
HDAC4 in the cell lysates.
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study also suggests that the abnormal accumulation or turnover of
RanBP2 and its substrates, including HDAC4, may contribute to neu-
ronal cell death in PD. Further studies will be required to determine
whether, and in whatmanner, abnormal RanBP2 processing plays a role
in PD pathogenesis.
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